BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21654267)

  • 41. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
    Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
    Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
    Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
    Hiramitsu S; Ishiguro Y; Matsuyama H; Yamada K; Kato K; Noba M; Uemura A; Matsubara Y; Yoshida S; Kani A; Tokuda M; Kato H; Hasegawa K; Uchiyama T; Matsubara S; Mori K; Kimura H; Shino K; Kato Y; Ishii J
    Clin Exp Hypertens; 2014; 36(6):433-40. PubMed ID: 24164405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Kamatani N; Hosoya T
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
    [No Abstract]   [Full Text] [Related]  

  • 47. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
    Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Zhao L; Johnson RJ
    Nephrol Dial Transplant; 2008 Apr; 23(4):1179-85. PubMed ID: 18048425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
    Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
    Grabowski BA; Khosravan R; Vernillet L; Mulford DJ
    J Clin Pharmacol; 2011 Feb; 51(2):189-201. PubMed ID: 20354234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol.
    Saito J; Matsuzawa Y; Ito H; Omura M; Ito Y; Yoshimura K; Yajima Y; Kino T; Nishikawa T
    Endocr Res; 2010; 35(4):145-54. PubMed ID: 20958145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
    Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
    Kataoka H; Yang K; Rock KL
    Eur J Pharmacol; 2015 Jan; 746():174-9. PubMed ID: 25449036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
    Tamura K; Kawai Y; Kiguchi T; Okamoto M; Kaneko M; Maemondo M; Gemba K; Fujimaki K; Kirito K; Goto T; Fujisaki T; Takeda K; Nakajima A; Ueda T
    Int J Clin Oncol; 2016 Oct; 21(5):996-1003. PubMed ID: 27017611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of hyperuricemia in gout: focus on febuxostat.
    Reinders MK; Jansen TL
    Clin Interv Aging; 2010 Feb; 5():7-18. PubMed ID: 20169038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.
    Li Y; Liu M; Zhang X; Lu Y; Meng J
    Ren Fail; 2019 Nov; 41(1):595-599. PubMed ID: 31267805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.